EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Cost-Effectiveness and Drug Survival of First-Line Versus Later-Line Guselkumab in Moderate-to-Severe Plaque Psoriasis

Bat Sheva Varda Berkovitch, Moshe Leshno, Daniel Mimouni, Lev Pavlovsky

Journal of Clinical Medicine · 15.11.2026 · 15 (22) · 8943

DOI: 10.3390/jcm15228943 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.11.2026. Verfasst von Bat Sheva Varda Berkovitch und 3 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Psoriasis is a common chronic inflammatory skin disorder, affecting approximately 0.6–1.1% of adults worldwide. Guselkumab, a selective interleukin (IL)-23 inhibitor, is highly effective in moderate-to-severe plaque psoriasis, yet in many healthcare systems it is reserved for patients who have failed lower-cost biologics. Real-world evidence on its cost-effectiveness as first-line versus later-line biologic therapy remains limited. This study evaluated drug survival and cost-effectiveness of guselkumab as first-line compared with later-line biologic therapy in moderate-to-severe plaque psoriasis.

Methods

This retrospective cohort study included 200 patients with moderate-to-severe plaque psoriasis treated with guselkumab at a tertiary medical center: 69 as first-line and 131 as later-line biologic therapy. Drug survival was analyzed using Kaplan–Meier curves and multivariable Cox regression, and clinical response using the Psoriasis Area and Severity Index (PASI). Costs and quality-adjusted life years (QALYs) over 10 years were estimated with a patient-level Markov microsimulation.

Results

First-line guselkumab was associated with longer drug survival (adjusted hazard ratio for discontinuation with later-line use 42.4, 95% confidence interval 5.3–342.1; p < 0.001). At last follow-up, with the most recent biologic agent received, PASI 100 was achieved by 72.1% of first-line versus 54.2% of later-line patients. In the 10-year model, first-line guselkumab yielded more QALYs (8.19 vs. 5.83) at a lower estimated cost per patient (584,731 vs. 673,201 Israeli new shekels) and remained dominant across all one-way sensitivity analyses.

Conclusions

In this real-world cohort and based on Israeli drug costs, first-line guselkumab was associated with longer persistence, better clinical response, and lower model-estimated costs than later-line use, supporting consideration of earlier initiation in moderate-to-severe plaque psoriasis.

Zitieren

APA

Berkovitch, B. S. V., Leshno, M., Mimouni, D., & Pavlovsky, L. (2026). Real-World Cost-Effectiveness and Drug Survival of First-Line Versus Later-Line Guselkumab in Moderate-to-Severe Plaque Psoriasis. Journal of Clinical Medicine, 15(22), 8943. https://doi.org/10.3390/jcm15228943

Vancouver

Berkovitch BSV, Leshno M, Mimouni D, Pavlovsky L. Real-World Cost-Effectiveness and Drug Survival of First-Line Versus Later-Line Guselkumab in Moderate-to-Severe Plaque Psoriasis. Journal of Clinical Medicine. 2026;15(22):8943. doi:10.3390/jcm15228943

BibTeX
@article{Berkovitch2026,
  author = {Berkovitch, Bat Sheva Varda and Leshno, Moshe and Mimouni, Daniel and Pavlovsky, Lev},
  title = {Real-World Cost-Effectiveness and Drug Survival of First-Line Versus Later-Line Guselkumab in Moderate-to-Severe Plaque Psoriasis},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {22},
  pages = {8943},
  doi = {10.3390/jcm15228943}
}
Kostenlos starten →